COVID-19 vaccine effectiveness
(Randomized evidence)

Methods

Protocol

Latest news:Last search date July 30, 2023. No further screening is planned after this date. Extraction is ongoing for all pending studies.

  • Results of booster studies are available in the tables below and are updated on a monthly basis.
  • As of December 14, 2022, the COVID-NMA revised its protocol and discontinued the inclusion of prime vaccination trials in its analysis. The analysis presented on this page for prime vaccines compared to placebo or other vaccines includes trials that were identified and included up to December 14, 2022. A list of studies that were eligible up to this date but not extracted is provided in detail here .
  • The vaccine review "Efficacy and safety of COVID‐19 vaccines" included 41 preprints and published trials of 12 different COVID-19 used as prime vaccination and that were published before 5 November 2021.

    meta-COVID

    Perform your own analysis using COVID-NMA data for prime vaccination (last search date 14/12/2022), create and download your forest plots by clicking below:

    go to metacovid

    COVID-19 BOOSTER DOSE VACCINATION: updated daily

    Vaccine efficacy, immunogenicity and safety of:

    First Boost

    • 1st booster VS no booster (tables)
    • 1st booster VS 1st booster (tables)

    Second Boost

    • 2nd booster VS 1st booster (tables)
    • 2nd booster VS 2nd booster (tables)

    COVID-19 PRIME VACCINATION: Last search date December 14, 2022.

    Click here to see Covid-19 prime vaccination studies

    Search studies

    Search by Vaccine name Author Registration number
    Trial Type Comparisons Design Participants Sample size Overall risk
    of bias
    Highest assessment
    Full description
    Intervention 1 Intervention 2
    CTRI/2021/01/030416
    Zydus Cadila
    Khobragade A, Lancet , 2022

    Full text
    Commentary
    DNA based vaccine

    ZyCoV-D 2mg D0/28/56

    Placebo

    RCT
    Phase 3
    Healthy adults and adolescents aged (≥12 years) with no previous history of COVID-19 at 49 centers in India. N= 27703
    Some concerns
    Details

    Full description

    NCT04642638
    Inovio Pharmaceuticals
    Mammen Jr M, medRxiv, 2021

    Full text
    Commentary
    Commentary
    DNA based vaccine

    INO-4800 1mg

    INO-4800 2mg

    Placebo 1

    Placebo 2

    RCT
    Phase 2
    Healthy adult volunteers SARS-CoV-2 seronegative at high risk of infection at 16 locations in the USA. N= 401
    Some concerns
    Details

    Full description